Claims for Patent: 6,335,034

Summary for Patent: 6,335,034

Title:	Topical drug preparations
Abstract:	Topical gelled compositions comprising an optional drug dispersed within a polymer matrix, methods of producing the same and treatments with the complex.
Inventor(s):	Drizen; Alan (Ontario, CA), Rothbart; Peter (Ontario, CA), Nath; Gary M. (Bethesda, MD)
Assignee:	L.A.M. Pharmaceutical Corporation (North York, CA)
Application Number:	09/537,257
Patent Claims:	1. A composition for treating pain in an animal for a sustained period of time, which comprises: a polymer matrix containing sodium hyaluronate and a nonionic polymer, said polymer matrix being suspended in a liquid medium; a therapeutically effective amount of a drug for treating pain dispersed within said polymer matrix; wherein the molar ratio of the sodium hyaluronate to the nonionic polymer is 1:0.5 to 4, said sodium hyaluronate being present in amounts of about 2.0% to about 3.5% by weight of said composition; and wherein said composition is topically applied to said animal to treat pain. 2. The composition of claim 1, wherein the drug for treating pain is selected from the group consisting of anesthetics, analgesics, nonsteroidal anti-inflammatory drugs (NSAIDS), steroids, hormones, antibiotics, metal salts, minerals and combinations thereof. 3. The composition of claim 2, wherein said anesthetic is selected from the group consisting of benzocaine, tetracaine, mepivacaine, prilocaine, etidocaine, bupivacaine, lidocaine and combinations thereof. 4. The composition of claim 2, wherein said analgesic is selected from the group consisting of acetaminophen, ibuprofen, fluriprofen, ketoprofen, voltaren, phenacetin, salicylamide and combinations thereof. 5. The composition of claim 2, wherein said non-steroidal anti-inflammatory drug (NSAID) is selected from the group consisting of diclofenac, naproxen, acetaminophen, ibuprofen, flurbiprofen, ketoprofen, phenacetin, salicylamide, indomethacin and combinations thereof. 6. The composition of claim 2, wherein said steroid is selected from the group consisting of anabolics, corticoids, glucocorticoids and combinations thereof. 7. The composition of claim 2, wherein said hormone is selected from the group consisting of ACTH, androgens, estrogens, gonadotropin, human growth hormone, hypocalcemic, menotropins, progesterone, progestogen, urofollitropin, vasopressin and combinations thereof. 8. The composition of claim 2, wherein the antibiotic is selected from the group consisting of erythromycin, penicillin, cephalosporins and combinations thereof. 9. The composition of claim 2, wherein the metal salt is selected from the group consisting of potassium chloride, lithium carbonate and combinations thereof. 10. The composition of claim 2, wherein the mineral is selected from the group consisting of iron, chromium, molybdenum, potassium and combinations thereof. 11. The composition of claim 1, wherein the drug for treating pain is diclofenac. 12. The composition of claim 11, wherein said diclofenac is selected from the group consisting of diclofenac sodium, diclofenac potassium and combinations thereof. 13. The composition of claim 1, wherein the molar ratio of the sodium hyaluronate to the nonionic polymer is 1:0.5 to 2. 14. The composition of claim 1, wherein said sodium hyaluronate has a sulphated ash content below about 15%, a protein content below about 5% and purity of at least 98%. 15. The composition of claim 1, wherein the pain is located in a joint, a ligament, a tendon, cartilage or muscle. 16. The composition of claim 1, wherein the pain is located in a knee, back, ankle, hand, foot or neck. 17. A composition for treating osteoarthritic pain in an animal for a sustained period of time, which comprises: a polymer matrix containing sodium hyaluronate and a nonionic polymer, said polymer matrix being suspended in a liquid medium; a therapeutically effective amount of a drug for treating osteoarthritic pain dispersed within said polymer matrix; wherein the molar ratio of the sodium hyaluronate to the nonionic polymer is 1:0.5 to 4, said sodium hyaluronate being present in amounts of about 2.0% to about 3.5% by weight of said composition; and wherein said composition is topically applied to said animal to treat osteoarthritic pain. 18. The composition of claim 17, wherein the molar ratio of the sodium hyaluronate to the nonionic polymer is 1:0.5 to 2. 19. The composition of claim 17, wherein said sodium hyaluronate has a sulphated ash content below about 15%, a protein content below about 5% and purity of at least 98%. 20. The composition of claim 17, wherein the drug for treating osteoarthritic pain is selected from the group consisting of anesthetics, analgesics, nonsteroidal anti-inflammatory drugs (NSAIDS), steroids, hormones, antibiotics, metal salts, minerals, and combinations thereof. 21. The composition of claim 17, wherein the drug for treating osteoarthritic pain is diclofenac. 22. The composition of claim 21, wherein said diclofenac is selected from the group consisting of diclofenac sodium, diclofenac potassium and combinations thereof. 23. A composition for treating osteoarthritis in an animal for a sustained period of time, which comprises: a polymer matrix containing sodium hyaluronate and a nonionic polymer, said polymer matrix being suspended in a liquid medium; a therapeutically effective amount of a drug for treating osteoarthritis, said drug being dispersed within said polymer matrix; wherein the molar ratio of the sodium hyaluronate to the nonionic polymer is 1:0.5 to 4, said sodium hyaluronate being present in amounts of about 2.0% to about 3.5% by weight of said composition; and wherein said composition is topically applied to said animal to treat osteoarthritis. 24. The composition of claim 23, wherein the drug for treating osteoarthritis is selected from the group consisting of anesthetics, analgesics, nonsteroidal anti-inflammatory drugs (NSAIDS), steroids, hormones, antibiotics, metal salts, minerals, and combinations thereof. 25. The composition of claim 23, wherein the drug for treating osteoarthritis is diclofenac. 26. The composition of claim 25, wherein said diclofenac is selected from the group consisting of diclofenac sodium, diclofenac potassium and combinations thereof.

Details for Patent 6,335,034

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emd Serono, Inc.	PERGONAL	menotropins	For Injection	017646	August 22, 1975		2020-03-29
Emd Serono, Inc.	PERGONAL	menotropins	For Injection	017646	May 20, 1985		2020-03-29
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc.	HUMEGON	menotropins	For Injection	020328	September 01, 1994		2020-03-29